In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

A new injectable weight loss treatment from the maker of Ozempic and Wegovy delivered 23% weight loss in trials, according to findings published in the New England journal and medicine. Dr. Roshini ...

Eli Lilly's tirzepatide and Boehringer Ingelheim's survodutide grab the spotlight at EASL with new phase 2 data in metabolic dysfunction-associated steatohepatitis (MASH) ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

The increasing prevalence of overweight and obesity in China poses an urgent public health challenge requiring immediate ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

The achievement of that goal in India, which ranks third in obesity numbers after the US and China, will shatter the record ...

Other GLP-1-targeted drugs including Eli Lilly's tirzepatide and Boehringer Ingelheim's survodutide have also shown promise in MASH, suggesting there could be multiple treatment options in the ...